|Table of Contents|

Research progress on the influence of metabolic syndrome on the occurrence and development of ovarian cancer based on PI3K/AKT signaling pathway

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 19
Page:
3786-3790
Research Field:
Publishing date:

Info

Title:
Research progress on the influence of metabolic syndrome on the occurrence and development of ovarian cancer based on PI3K/AKT signaling pathway
Author(s):
LI Liangzhe1; MA Yuting1; LIU Fangyuan2; DING Danni1; HAN Fengjuan2
1.Heilongjiang University of Chinese Medicine,Heilongjiang Harbin 150000,China;2.The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Heilongjiang Harbin 150000，China.
Keywords:
metabolic syndrome; PI3K/AKT signal pathway; ovarian cancer
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2024.19.028
Abstract:
Metabolic syndrome is characterized by a series of metabolic abnormalities,such as insulin resistance,abdominal obesity,elevated blood pressure,with a high incidence rate in recent years.Ovarian cancer is one of the most common cancers of the female reproductive system.Some studies have shown that metabolic syndrome can promote the occurrence and development of ovarian cancer.PI3K/AKT signal pathway is a frequently changed signal pathway in ovarian cancer.By searching multiple Chinese and English databases,we found that PI3K/AKT signal pathway is associated with metabolic diseases such as diabetes,obesity and hypertension.However,there has been no in-depth study on the role of metabolic syndrome and PI3K/AKT signal pathway in the pathogenesis of ovarian cancer.Based on this,this paper further discusses the impact of abnormal manifestations of metabolic syndrome on the occurrence and development of ovarian cancer through the PI3K/AKT signal pathway,in order to deeply understand the molecular mechanism of ovarian cancer-related metabolic syndrome,so as to provide new ideas for the prevention,control and treatment of ovarian cancer.

References:

［1］CABASAG CJ,FAGAN PJ,FERLAY J,et al.Ovarian cancer today and tomorrow:A global assessment by world region and human development index using GLOBOCAN 2020［J］.Int J Cancer,2022,151(9):1535-1541.
［2］徐杰茹，陈磊，张敏，等.1990-2019年中国卵巢癌发病与死亡趋势及其年龄-时期-队列模型分析［J］.中国肿瘤,2022,31(4):276-283. XU JR,CHEN L,ZHANG M,et al.Incidence and mortality trend of ovarian cancer and its age-period-cohort model analysis in China from 1990 to 2019［J］.Chinese Oncology,2022,31(4):276-283.
［3］MIAO MQ,HAN YB,LIU L.Mitophagy in metabolic syndrome［J］.The Journal of Clinical Hypertension,2023,25(5):397-403.
［4］KARMALI R,DALOVISIO A,BORGIA JA,et al.All in the family:Clueing into the link between metabolic syndrome and hematologic malignancies［J］.Blood Reviews,2015,29(2):71-80.
［5］MICHELS KA,MCNEEL TS,TRABERT B.Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States:An analysis of linked SEER-medicare data［J］.Gynecologic Oncology,2019,155(2):294-300.
［6］YANG X,WANG J.The role of metabolic syndrome in endometrial cancer:A review［J］.Frontiers in Oncology,2019,9:744.
［7］PING P,LI J,LEI H,et al.Fatty acid metabolism:A new therapeutic target for cervical cancer［J］.Frontiers in Oncology,2023,13:1111778.
［8］DONG S,WANG Z,SHEN K,et al.Metabolic syndrome and breast cancer:Prevalence,treatment response,and prognosis［J］.Frontiers in Oncology,2021,11:629666.
［9］高晨曦,卢辉,邓雷,等.代谢综合征与高龄女性卵巢癌的相关性［J］.中国医科大学学报,2020,49(9):818-823. GAO CX,LU H,DENG L,et al.Correlation between metabolic syndrome and ovarian cancer in elderly women［J］.Journal of China Medical University,2020,49(9):818-823.
［10］SUN W,LU J,WU S,et al.Association of insulin resistance with breast,ovarian,endometrial and cervical cancers in non-diabetic women［J］.American Journal of Cancer Research,2016,6(10):2334.
［11］LIU Y,ZHANG TT,ZHAO JJ,et al.Meta analysis of the correlation between overweight,obesity and ovarian cancer［J］.Japanese Journal of Clinical Oncology,2015,45(12):1107-1115.
［12］童露瑶,雷理仪,陈军,等.代谢综合征及其组分与卵巢癌发病风险的关系［J］.实用医学杂志,2022,38(10):1280-1285. TONG LY,LEI LY,CHEN J,et al.Relationship between metabolic syndrome and its components and the risk of ovarian cancer［J］.Journal of practical Medicine,2022,38(10):1280-1285.
［13］EDIRIWEERA MK,TENNEKOON KH,SAMARAKOON SR.Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:Biological and therapeutic significance［J］.Seminars in Cancer Biology,2019,59:147-160.
［14］SHI X,WANG J,LEI Y,et al.Research progress on the PI3K/AKT signaling pathway in gynecological cancer［J］.Molecular Medicine Reports,2019,19(6):4529-4535.
［15］KINROSS KM,MONTGOMERY KG,KLEINSCHMIDT M,et al.An activating PIK3CA mutation coupled with PTEN loss is sufficient to initiate ovarian tumorigenesis in mice［J］.The Journal of Clinical Investigation,2012,122(2):553-557.
［16］LIU X,ZHANG J,DUAN Z,et al.Nck1 promotes the progression of ovarian carcinoma by enhancing the PI3K/AKT/p70S6K signaling［J］.Human Cell,2020,33:768-779.
［17］PASSARELLI A,CARBONE V,PIGNATA S,et al.Alpelisib for PIK3CA-mutated advanced gynecological cancers:First clues of clinical activity［J］.Gynecologic Oncology,2024,183:61-67.
［18］AJALA-LAWAL RA,ALIYU NO,AJIBOYE TO.Betulinic acid improves insulin sensitivity,hyperglycemia,inflammation and oxidative stress in metabolic syndrome rats via PI3K/Akt pathways［J］.Archives of Physiology and Biochemistry,2020,126(2):107-115.
［19］JOUNG KH,JEONG JW,KU BJ.The association between type 2 diabetes mellitus and women cancer:The epidemiological evidences and putative mechanisms［J］.BioMed Research International,2015,2015:2314-6133.
［20］LEE JY,JEON IP,KIM JW,et al.Diabetes mellitus and ovarian cancer risk:A systematic review and Meta-analysis of observational studies［J］.International Journal of Gynecologic Cancer,2013,23(3):402-412.
［21］KERR A,BAXTER RC.Noncoding RNA actions through IGFs and IGF binding proteins in cancer［J］.Oncogene,2022,41(25):3385-3393.
［22］MATSUSHITA M,FUJITA K,HATANO K,et al.Connecting the dots between the Gut-IGF-1-prostate axis:A role of IGF-1 in prostate carcinogenesis［J］.Frontiers in Endocrinology,2022,13:852382.
［23］WEYER-CZERNILOFSKY U,HOFMANN MH,FRIEDBICHLER K,et al.Antitumor activity of the IGF-1/IGF-2-neutralizing antibody xentuzumab(BI 836845) in combination with enzalutamide in prostate cancer models［J］.Molecular Cancer Therapeutics,2020,19(4):1059-1069.
［24］ALAGARATNAM S,LOIZIDOU M,YANG S,et al.Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and colorectal cancer［J］.Journal of Cancer Research and Clinical Oncology,2020,146:2861-2870.
［25］MOLNAR K,MESZAROSA,FAZAKAS C,et al.Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation［J］.Molecular Oncology,2020,14(9):2040-2057.
［26］郑小妹,林叶飞,张韶琼,等.IGF1调控PI3K/AKT信号通路对卵巢癌细胞增殖和侵袭的影响［J］.中国计划生育和妇产科,2023,15(4):32-37. ZHENG XM,LIN YF,ZHANG SQ,et al.Effect of IGF1 regulating PI3K/AKT signal pathway on proliferation and invasion of ovarian cancer cells［J］.China Family Planning and Obstetrics and Gynecology,2023 15(4):32-37.
［27］WALLACH EE,NOBELS F,DEWAILLY D.Puberty and polycystic ovarian syndrome:The insulin/insulin-like growth factor I hypothesis［J］.Fertility and Sterility,1992,58(4):655-666.
［28］CROSBIE EJ,ZWAHLEN M,KITCHENER HC,et al.Body mass index,hormone replacement therapy,and endometrial cancer risk:A Meta-analysis［J］.Cancer Epidemiology,Biomarkers & Prevention,2010,19(12):3119-3130.
［29］LI Y,LI S,ZHANG Y,et al.Androgen plays a carcinogenic role in EOC via the PI3K/AKT signaling pathway in an AR-dependent manner［J］.Journal of Cancer,2021,12(6):1815.
［30］HUA K,FENG W,CAO Q,et al.Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer［J］.International Journal of Oncology,2008,33(5):959-967.
［31］BENEDET JL,PECORELLI S,NGAN HY,et al.Staging classifications and clinical practice guidelines for gynaecological cancers［J］.International Journal of Gynecology and Obstetrics,2000,70:37-62.
［32］CRAIG ER,LONDONO AI,NORIAN LA,et al.Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer:A review［J］.Gynecologic Oncology,2016,143(3):674-683.
［33］PROTANI MM,NAGLE CM,WEBB PM.Obesity and ovarian cancer survival:A systematic review and meta-analysis［J］.Cancer prevention research,2012,5(7):901-910.
［34］DIJKGRAAF EM,WELTERS MJ,NORTIER JW,et al.Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer［J］.Curr Pharm Des,2012,18(25):3816-3827.
［35］ZHAO YL,SUN Y,HUANG SH,et al.IL-6 induces the resistance of ovarian cancer cells to tamoxifen via PI3K/Akt pathway［J］.Chinese Journal of Biotherapy of Oncology,2017,24(6):601-607.
［36］SZLOSAREK PW,GRIMSHAW MJ,KULBE H,et al.Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium［J］.Molecular Cancer Therapeutics,2006,5(2):382-390.
［37］HU S,CHANG X,ZHU H,et al.PI3K mediates tumor necrosis factor induced-necroptosis through initiating RIP1-RIP3-MLKL signaling pathway activation［J］.Cytokine,2020,129:155046.
［38］JIN Y,QIU S,SHAO N,et al.Fucoxanthin and tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) synergistically promotes apoptosis of human cervical cancer cells by targeting PI3K/Akt/NF-κB signaling pathway［J］.Medical Science Monitor,2018,24:11.
［39］ABALLAY LR,EYNARD AR,DIAZ MP,et al.Overweight and obesity:A review of their relationship to metabolic syndrome,cardiovascular disease,and cancer in South America［J］.Nutrition Reviews,2013,71(3):168-179.
［40］JIN JH,KIM HJ,KIM CY,et al.Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer［J］.Obstetrics & Gynecology Science,2016,59(4):279-285.
［41］ZHOU L,DEEPA SS,ETZLER JC,et al.Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways［J］.Journal of Biological Chemistry,2009,284(33):22426-22435.
［42］BORON D,NOWAKOWSKI R,GRABAREK BO,et al.Expression pattern of leptin and its receptors in endometrioid endometrial cancer［J］.Journal of Clinical Medicine,2021,10(13):2787.
［43］CHEN YC,CHIEN CY,HSU CC,et al.Obesity-associated leptin promotes chemoresistance in colorectal cancer through YAP-dependent AXL upregulation［J］.American Journal of Cancer Research,2021,11(9):4220.
［44］HARBUZARIU A,RAMPOLDI A,DALEY-BROWN DS,et al.Leptin-Notch signaling axis is involved in pancreatic cancer progression［J］.Oncotarget,2017,8(5):7740.
［45］BARONE I,GIORDANO C.Leptin and beyond:Actors in cancer［J］.Biomolecules,2021,11(12):1836.
［46］RAY A,FORNSAGLIO J,DOGAN S,et al.Gynaecological cancers and leptin:A focus on the endometrium and ovary［J］.Facts,Views & Vision in Obgyn,2018,10(1):5.
［47］GU F,ZHANG H,YAO L,et al.Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer［J］.Oncology Letters,2019,18(1):561-570.
［48］CHIN YT,WANG LM,HSIEH MT,et al.Leptin OB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells［J］.Journal of Biomedical Science,2017,24:1-13.
［49］UDDIN S,BU R,AHMED M,et al.Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer［J］.Molecular Cancer,2009,8:1-12.
［50］CHEN C,CHANG YC,LAN MS,et al.Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways［J］.International Journal of Oncology,2013,42(3):1113-1119.
［51］LONCASTER JA,COOPER RA,LOGUE JP,et al.Vascular endothelial growth factor(VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix［J］.British Journal of Cancer,2000,83(5):620-625.
［52］ALROBAIQ BM,ALHARBI RS,ALHOSHAN FS,et al.Hypertension and ovarian cancer:A case-control study in Saudi Arabia［J］.Cureus,2023,15(2):2168-2184.
［53］HUANG T,POOLE EM,ELIASSEN AH,et al.Hypertension,use of antihypertensive medications,and risk of epithelial ovarian cancer［J］.International Journal of Cancer,2016,139(2):291-299.
［54］JIANG BH,ZHENG JZ,AOKI M,et al.Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells［J］.Proceedings of the National Academy of Sciences,2000,97(4):1749-1753.
［55］HU L,HOFMANN J,JAFFE RB.Phosphatidylinostol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma［J］.Clinical Cancer Research,2005,11(22):8208-8212.
［56］QIN B,MOORMAN PG,KELEMEN LE,et al.Dietary quality and ovarian cancer risk in African-American women［J］.American Journal of Epidemiology,2017,185(12):1281-1289.

Memo

Memo:
National Natural Science Foundation of China(No.82274566,82074484);国家自然科学基金项目（编号：82274566,82074484）
Last Update: 2024-08-30